Lantern Pharma Inc (LTRN) Stock Price, Quote & News

Company Profile

Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 277 1136

Website: www.lanternpharma.com

Address:

1920 McKinney Avenue, 7th Floor, Dallas, United States

Goheat207 Aug. 7 at 5:17 PM

All these people with such crazy Sell spreads on $LTRN just hate to see people make money...!!!

0 · Reply

Goheat207 Aug. 7 at 1:48 PM

SOMEONE PLEASE EXPLAIN TO ME HOW A STOCK CAN HAVE PRETTY GOOD NEWS BUT STILL NOT MOVE.? $LTRN

0 · Reply

BigSqueezeComing Aug. 7 at 11:14 AM

$LTRN going higher!!!

0 · Reply

BigSqueezeComing Aug. 7 at 11:13 AM

$LTRN https://finance.yahoo.com/m/2298d58b-69a6-3f5d-aaa3-b76239a72f64/fda-clears-starlight.html

0 · Reply

Nismo325 Aug. 6 at 9:26 PM

$LTRN why is yahoo showing an after hours price of 5.71 and this shows it dropped to 5.00 after hours?

0 · Reply

NetworkNewsWire Aug. 6 at 4:50 PM

$LTRN – Lantern Pharma Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial https://ibn.fm/0hfZr

0 · Reply

Slapshot22 Aug. 6 at 1:21 AM

$LTRN Seems like we should be getting an Q2 ER announcement here shortly. Have not seen much on it yet ... and getting close. Will be interesting to see the latest. GLA. 2024 took place on Aug 8th. "Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET"

0 · Reply

WOLFSTREET Aug. 5 at 2:27 AM

$LTRN Up 20% YTD !! This is a CC BIO "RE-Play", so just been in on a PENNY ticker, and this one, there are others, but you know about those... You do not need to "MEME" , You need to "CCCC"

0 · Reply

Drugtrade Aug. 4 at 7:26 PM

$LTRN $100 long term 1 billion market cap easy

0 · Reply

NetworkNewsWire Aug. 4 at 7:14 PM

AINewsBreaks – $LTRN Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy https://ibn.fm/eDdN6

0 · Reply

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

Aug 4, 2025, 8:55 AM EDT - 3 days ago

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

Jul 31, 2025, 7:30 AM EDT - 7 days ago

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

Jul 28, 2025, 8:00 AM EDT - 10 days ago

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

Jul 23, 2025, 7:56 AM EDT - 15 days ago

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

Jul 21, 2025, 8:20 AM EDT - 17 days ago

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

Jul 15, 2025, 9:40 AM EDT - 23 days ago

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

Jun 16, 2025, 8:30 AM EDT - 7 weeks ago

Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

May 29, 2025, 8:30 AM EDT - 2 months ago

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

May 15, 2025, 3:04 PM EDT - 2 months ago

Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript

May 15, 2025, 8:45 AM EDT - 3 months ago

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

May 12, 2025, 9:00 AM EDT - 3 months ago

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

May 8, 2025, 8:30 AM EDT - 3 months ago

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

May 5, 2025, 8:55 AM EDT - 3 months ago

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

Mar 27, 2025, 8:35 PM EDT - 4 months ago

Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:01 PM EDT - 4 months ago

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Mar 20, 2025, 8:00 AM EDT - 5 months ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

Feb 19, 2025, 8:00 AM EST - 6 months ago

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Jan 27, 2025, 7:55 AM EST - 6 months ago

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

Dec 9, 2024, 8:15 AM EST - 8 months ago

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Dec 3, 2024, 8:00 AM EST - 8 months ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Nov 26, 2024, 8:45 AM EST - 9 months ago

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Nov 19, 2024, 8:00 AM EST - 9 months ago

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Nov 8, 2024, 7:23 PM EST - 9 months ago

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 9 months ago

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Nov 5, 2024, 8:00 AM EST - 9 months ago

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Oct 31, 2024, 8:00 AM EDT - 10 months ago

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Oct 23, 2024, 8:45 AM EDT - 10 months ago

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Oct 21, 2024, 8:00 AM EDT - 10 months ago

Lantern Pharma to Host & Participate in Two Public Webinars During October

Oct 15, 2024, 9:07 AM EDT - 10 months ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Sep 23, 2024, 8:00 AM EDT - 11 months ago

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers

Aug 10, 2024, 4:01 AM EDT - 1 year ago

Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Aug 7, 2024, 9:31 AM EDT - 1 year ago

Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

Jul 10, 2024, 8:30 AM EDT - 1 year ago

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Jun 12, 2024, 7:30 AM EDT - 1 year ago

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

May 9, 2024, 4:02 PM EDT - 1 year ago

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

May 6, 2024, 3:00 AM EDT - 1 year ago

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

May 2, 2024, 7:30 AM EDT - 1 year ago

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

Apr 24, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Apr 22, 2024, 8:12 AM EDT - 1 year ago

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Mar 18, 2024, 11:14 PM EDT - 1 year ago

Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript

Mar 18, 2024, 4:02 PM EDT - 1 year ago

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Mar 11, 2024, 7:30 AM EDT - 1 year ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

Mar 5, 2024, 8:01 AM EST - 1 year ago

Lantern To Participate in H.C Wainwright & Co.'s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Mar 4, 2024, 8:01 AM EST - 1 year ago

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

Feb 15, 2024, 8:01 AM EST - 1 year ago

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

Goheat207 Aug. 7 at 5:17 PM

All these people with such crazy Sell spreads on $LTRN just hate to see people make money...!!!

0 · Reply

Goheat207 Aug. 7 at 1:48 PM

SOMEONE PLEASE EXPLAIN TO ME HOW A STOCK CAN HAVE PRETTY GOOD NEWS BUT STILL NOT MOVE.? $LTRN

0 · Reply

BigSqueezeComing Aug. 7 at 11:14 AM

$LTRN going higher!!!

0 · Reply

BigSqueezeComing Aug. 7 at 11:13 AM

$LTRN https://finance.yahoo.com/m/2298d58b-69a6-3f5d-aaa3-b76239a72f64/fda-clears-starlight.html

0 · Reply

Nismo325 Aug. 6 at 9:26 PM

$LTRN why is yahoo showing an after hours price of 5.71 and this shows it dropped to 5.00 after hours?

0 · Reply

NetworkNewsWire Aug. 6 at 4:50 PM

$LTRN – Lantern Pharma Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial https://ibn.fm/0hfZr

0 · Reply

Slapshot22 Aug. 6 at 1:21 AM

0 · Reply

WOLFSTREET Aug. 5 at 2:27 AM

$LTRN Up 20% YTD !! This is a CC BIO "RE-Play", so just been in on a PENNY ticker, and this one, there are others, but you know about those... You do not need to "MEME" , You need to "CCCC"

0 · Reply

Drugtrade Aug. 4 at 7:26 PM

$LTRN $100 long term 1 billion market cap easy

0 · Reply

NetworkNewsWire Aug. 4 at 7:14 PM

AINewsBreaks – $LTRN Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy https://ibn.fm/eDdN6

0 · Reply

Slapshot22 Aug. 4 at 7:13 PM

$LTRN Perhaps the quietest "up more than 10% today stock" on the market. Ok with that. Bought it as a bit of a sleeper. As long as it keeps trending up, we're ok.

0 · Reply

Daddy044 Aug. 2 at 9:13 PM

$LTRN Biotech continuing the breakout and this one has endless possibilities. Lots of news flow for unknown AI biotech.

0 · Reply

mankind1 Aug. 1 at 5:25 PM

$LTRN good stuff.

0 · Reply

NetworkNewsWire Jul. 31 at 7:20 PM

BioMedNewsBreaks — $LTRN Completes Targeted Enrollment for Phase 2 HARMONIC Trial in Japan https://ibn.fm/CDFsL

0 · Reply

Doozio Jul. 31 at 2:55 PM

$LTRN its chop chop huckleberries 🐒🍌🧠⏰♾️

0 · Reply

mankind1 Jul. 31 at 2:39 PM

$LTRN did I miss something? someone give me some info

1 · Reply

Drugtrade Jul. 30 at 4:23 PM

$LTRN $100 long term target

0 · Reply

NetworkNewsWire Jul. 28 at 7:20 PM

AINewsBreaks – $LTRN Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology https://ibn.fm/MnUJD

0 · Reply

srcntzg Jul. 28 at 12:46 PM

$LTRN https://www.businesswire.com/news/home/20250728895931/en/Lantern-Pharma-Announces-Appointment-of-Dr.-Lee-Schalop-to-Board-of-Directors

0 · Reply

MetroRock1000 Jul. 26 at 1:42 AM

$LTRN Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV https://finance.yahoo.com/news/lantern-pharma-interview-air-redchip-130000625.html

0 · Reply

TimothyJackson791 Jul. 24 at 4:53 PM

$LTRN has pipeline ambition, but RMTG is running an active revenue model—Puerto Rico now joins their global clinic network generating real returns.

0 · Reply

PinTheInvestor Jul. 24 at 2:39 PM

Would be nice if somebody would pick up yesterday's complete response story. Hard to generate excitement if even $LTRN hasn't bothered to put it on their website yet... https://www.lanternpharma.com/media/news

0 · Reply

Market Cap	56.08M
Revenue (ttm)	0.00
Net Income (ttm)	-20.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	109,537
Avg Vol	278,120
Day's Range	N/A - N/A
Shares Out	10.79M
Stochastic %K	77%
Beta	1.60
Analysts	Strong Sell
Price Target	$25.50